Future Science Group
Browse
Download file
Download file
1/1
2 files

Supplementary Material: Infrequent Liver injury From Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Download all (256.25 kB)
figure
posted on 2022-03-02, 09:53 authored by Robert J. Fontana, Irene Tsung, Ihab Kassab, Linnea Swanson, Francis P. Worden

Supplemental Figure 1. Patient survival after starting cemiplimab immunotherapy for advanced cSCC.

The overall patient survival in the 4 patients who developed liver injury was not significantly different versus those without liver injury. (p = 0.99 Kaplan‐Meier statistics).

Abbreviations: cSCC = cutaneous squamous cell carcinoma

Supplemental Table 1. Clinical characteristics and outcomes of solid organ transplants recipients with cutaneous squamous cell carcinoma receiving cemiplimab monotherapy.

Abbreviations: YO = year old; M = male, F = female; irAEs = immune related adverse events

History

Usage metrics

    ImmunotherapyImmunotherapy

    Categories

    Keywords

    solid organ transplantationhepatoxicitydrug induced liver injuryimmune-mediated liver injury caused by immune checkpoint inhibitors,immune checkpoint inhibitorscutaneous squamous cell carcinomaCemiplimabCancer Therapy (excl. Chemotherapy and Radiation Therapy)Transplantation Immunology

    Licence

    CC BY-NC-ND 4.0

    Exports